Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients-Reference-Cited by-同舟云学术

Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients

Published:2013-09 Issue:5 Volume:5 Page:801-809
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Ladenstein Ruth,Weixler Silke,Baykan Bianca,Bleeke Matthias,Kunert Renate,Katinger Dietmar,Pribill Ingrid,Glander Petra,Bauer Steffen,Pistoia Vito,Michon Jean,Garaventa Alberto,Lode Holger N.

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.4161/mabs.25215

Reference29 articles.

1. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice

2. Dose Finding Study for the Use of Subcutaneous Recombinant Interleukin-2 to Augment Natural Killer Cell Numbers in an Outpatient Setting for Stage 4 Neuroblastoma After Megatherapy and Autologous Stem-Cell Reinfusion

3. Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid

4. Monoclonal antibodies: versatile platforms for cancer immunotherapy

5. Anti-GD2 strategy in the treatment of neuroblastoma

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune Microenvironment in Childhood Cancers: Characteristics and Therapeutic Challenges;Cancers;2024-06-12

2. Bispecific GD2 x B7-H3 Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma;2024-05-28

3. The Neuroblastoma Microenvironment, Heterogeneity and Immunotherapeutic Approaches;Cancers;2024-05-13

4. GD2-targeting therapy: a comparative analysis of approaches and promising directions;Frontiers in Immunology;2024-03-15

5. Toxicity Spectrum of Anti-GD2 Immunotherapy: A Real-World Study Leveraging the US Food and Drug Administration Adverse Event Reporting System;Pediatric Drugs;2023-12-28